Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial

AI Briefing

• – Pfizer and Valneva's Lyme disease vaccine shows 70% efficacy in clinical trial
• – Promising results despite fewer cases than expected
• – Paving the way for regulatory approval